Publication date: Available online 15 November 2026 Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry Author(s): Lijun Ma, Wenzhuo Wei, Wenwei Deng, Jin Chang, Mengmeng Xiao, Wenjie Yin, Mingyu Chen, Haoyang Lei, Kai Wang, Nan Li, Xiaoming Li
Differential neural mechanisms of hypnosis and progressive muscle relaxation in reducing social anxiety symptoms. // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – URL: https://www.sciencedirect.com/science/article/pii/S0278584626004021?dgcid=rss_sd_all
Differential neural mechanisms of hypnosis and progressive muscle relaxation in reducing social anxiety symptoms. Progress in Neuro-Psychopharmacology & Biological Psychiatry. https://www.sciencedirect.com/science/article/pii/S0278584626004021?dgcid=rss_sd_all
“Differential neural mechanisms of hypnosis and progressive muscle relaxation in reducing social anxiety symptoms.” Progress in Neuro-Psychopharmacology & Biological Psychiatry.
@article{article62910,
title = {Differential neural mechanisms of hypnosis and progressive muscle relaxation in reducing social anxiety symptoms},
journal = {Progress in Neuro-Psychopharmacology \& Biological Psychiatry},
url = {https://www.sciencedirect.com/science/article/pii/S0278584626004021?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...